You cannot select more than 25 topics
Topics must start with a letter or number, can include dashes ('-') and can be up to 35 characters long.
109 lines
9.1 KiB
Markdown
109 lines
9.1 KiB
Markdown
# Cambios [[2024/02]]
|
|
- ## Mensaje de [[Ale]] el [[2024/02/20]]
|
|
- #+BEGIN_VERSE
|
|
Hola Borja. De acuerdo en moverlo en esta dirección. Busquemos que el proyecto sea **reconocible por sus actividades y gente** lo antes posible, y poder usarla para **generar colaboraciones y claridad en el ámbito de salud global y NTDs** .
|
|
|
|
Van respuestas en rojo intercaladas a tus comentarios.
|
|
|
|
Tenemos pendiente definir que hacer con las [[Redes sociales]]. Ya van 8 meses de proyecto y podemos hacer un balance.
|
|
|
|
Destacaría el Estudio ALIVE en la página inicial.
|
|
|
|
Y sumar a los nombres de la gente. Arranquemos con el Steering Committee y pidiendo datos, opiniones, fotos, CV; lo que mejor les parezca.
|
|
|
|
Hasta se podría reflejar Annual meeting, visitas a [[WHO]] y a [[Ghana]] si se busca dar algo de color
|
|
|
|
#+END_VERSE
|
|
-
|
|
- Hay que incorporar mucha información técnica que permita a otros investigadores conocer los detalles del proyecto. La web no es solo para público general.
|
|
- Asuntos a incluir:
|
|
- ## Objetivos generales y objetivos específicos del proyecto.
|
|
- *Overall goal*: Support the achievement of the [[WHO]] 2030 NTD Roadmap for [[STH]] and beyond
|
|
- *Project purpose*: Advance and accelerate an innovative pharmacological tool to support the elimination goals against [[STH]] species, specially those poorly responsive to current treatment regimens
|
|
- *The intervention*: A single tablet, [[Fixed-Dose Combination]] of Ivermectin and [[Albendazole]]
|
|
- *Specific objectives*:
|
|
- Provide a tool to support the achievement of the [[WHO]] Roadmap goals for [[STH]]
|
|
- Submission process of [[FDC]] to EMA & national agencies in [[Ghana]] and Kenya
|
|
- Safety and effectiveness tailored to policy makers for the control of [[STH]], including [[Strongyloides stercolaris]] and integration with other NTDs
|
|
- Acceptability, feasibility and adherence data added to the evidence package to support [[WHO]] guidance
|
|
- Develop a model for sustainable supply and costing
|
|
- Model the impact of different use cases and scenarios
|
|
- Pilot antihelmintic resistance surveillance based on genetic epidemiology
|
|
- ## Basic facts del proyecto
|
|
- En qué call de EDCTP (Global Health EDCTP3) ha salido
|
|
- Project duration (36 months); cuando empieza y cuando acaba (20 junio 2026)
|
|
- Cuáles son los Work Packages y quién los lidera
|
|
- ## Timeline y milestones (cuáles se han cumplido?)
|
|
- __Proposed safety and effectiveness study__
|
|
- *Primary objective*: To evaluate and compare safety of a [[FDC]] against [[Albendazole]] alone via [[MDA]] in two study areas in Kenya and [[Ghana]].
|
|
- *Secondary objectives*:
|
|
- To evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[Albendazole]] against [[STH]] (T. trichiura, A. lumbricoides, hookworms) [[by]] microscopy
|
|
- To evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[Albendazole]] against [[Strongyloides stercolaris]] [[by]] serology
|
|
- *Primary goal*: Safety (incidence of SAEs)
|
|
- *Secondary goals*: Effectiveness at 21 days and 1 [[year]]; Genomic resistance
|
|
- *Sample size*: approx. 20k.
|
|
- *Target population*: School based
|
|
- *Epidemiologic conditions of the sites*: T. trichiura ongoing transmission areas
|
|
- *Countries*: [[Ghana]] and [[Kenya]]
|
|
- __Proposed acceptability and feasibility study__
|
|
- *Primary goal*: Acceptability and feasibility
|
|
- *Secondary goals*: Adherence (3-day regimen), fidelity
|
|
- *Countries*: [[Ghana]] and [[Kenya]]
|
|
- *Epidemiologic conditions of the sites*: Ongoing [[STH]] deworming activities
|
|
- ## Objetivos y logros de los proyectos STOP previos (en background)
|
|
- Qualification at EMA for art. 58
|
|
- Safety of IVM up to 600μg/kg alone and in coformulation with albendazole
|
|
- Demonstrated efficacy against T. trichiura in a pivotal trial in Sub-Saharan Africa
|
|
- No stopping rules were reached
|
|
- Safety was adequate
|
|
- Palatability results confirm adecuacy of size, taste and smell
|
|
- Superior efficacy against T. trichiura confirms a comprehensive spectrum against STH
|
|
- Los papers más relevantes que salieran de los previos STOP
|
|
- ## Otros facts
|
|
- FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016)
|
|
- Dosing strategies for Ivermectine are being revisited
|
|
- The fix-dose coformulation of Albendazole/Ivermectine is due to enter regulatory agencies
|
|
- Acceptability and safety studies are underway
|
|
- The access plan is being developed
|
|
- Integration across programs (these results have implications beyond STH)
|
|
- Progress has been achieved through public-private partnerships but more partners are needed to reach the ultimate goal.
|
|
- ## Investigadores principales de cada uno de los partners
|
|
- TODO Mandar un email y pedirles nombres para saber a quiénes citamos en la web y cómo quieren que los mostremos (Foto? enlace a LinkedIn? a página personal de su institución? crear una pequeña bio de cada uno en la web de stop2030?)
|
|
- ## Abstract del proyecto
|
|
- [[Soil-Transmitted Helminths]] (STH) remain a significant public health problem with recognized obstacles for control and elimination with the current benzimidazole regimens in [[Mass Drug Administration]] (MDA) campaigns. Renewed targets from [[WHO]] for 2030 include elimination of [[STH]] morbidity in pre-school and school age children (PSAC & SAC), increased country governance and financial support and a strongyloidiasis control program; 2030 has also been targeted by [[WHO]] for controlling NTDs to attain the Sustainable Development Goals.
|
|
|
|
The current proposal aims at accelerating the implementation of an innovative [[health]] technology, a [[Fixed-Dose Combination]] (FDC) tablet of co-formulated [[albendazole]] and ivermectin, with adequate safety and significantly superior efficacy against T. trichiura in a registrational randomized clinical trial. This trial is being conducted in Ethiopia, [[Kenya]] and Mozambique with the guidance of EMA and sponsored [[by]] [[EDCTP]] (STOP projects) with a Phase II trial completed and a Phase III currently recruiting.
|
|
|
|
This [[project]], [[STOP2030]], seeks to complement the results of the safety and efficacy trial with a field-based safety and effectiveness clinical study, acceptability studies in [[Ghana]] and [[Kenya]], modelling and cost-effectiveness exercises. The resulting information will be consolidated to build a multidisciplinary package for policy making and [[WHO]] guidance with the support of advocacy and communication activities to reach stakeholders and maximize the exploitation and impact of the [[FDC]] for [[STH]] control and elimination.
|
|
|
|
The Consortium assembled to execute the [[STOP2030]] proposal combines expertise in complementary fields [[from]] program assessment and implementation through Ministries of [[Health]] in sub Saharan African countries, advocacy, state of the art technology, leadership in clinical research and a pharma that has shown commitment for generating access to drugs against NTDs and has recently obtained [[WHO]] prequalification for generic ivermectin #INFO
|
|
-
|
|
-
|
|
- # Mensaje a [[Nerea]] con las instrucciones
|
|
- Hola, [[Nerea]]:
|
|
Te adjunto las instrucciones de lo que tenemos que empezar a cambiar de la página [[web]]:
|
|
- ## HOME
|
|
- ### Background
|
|
- Especificar que la novel formulation es una fixed-dose coformulation de [[Ivermectina]] y [[Albendazol]].
|
|
- Especificar que esta fixed-dose coformulation de ivm/alb has the lowest [[level]] of investment risk of all candidates for Combinations for [[STH]] treatment (fuente: Soil Transmitted Helminths Drug Combinations Expert Meeting, 2016, Gates Foundation)
|
|
- Una referencia explícita al Estudio ALIVE: https://gatesopenresearch.org/articles/6-62/v1
|
|
- Los achievements de los STOP previos
|
|
- Qualification at EMA for [[article]] 58 (ahora se llama Meds4All, creo)
|
|
- Proved safety of ivermectin of up to 600ug/kg both alone and in coformulation with [[albendazole]]
|
|
- Demonstrated efficacy of the [[FDC]] against T. trichiura
|
|
-
|
|
- ### Project
|
|
- Trabajamos para hacer 2 ensayos clínicos
|
|
- Un safety and effectiveness study
|
|
- Primary objective: evaluate and compare safety of the [[FDC]] against [[albendazole]] alone via [[MDA]] in two study areas in [[Kenya]] and [[Ghana]]
|
|
- Secondary objectives:
|
|
- Evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[albendazole]] against [[STH]] by microscopy
|
|
- Evaluate the effectiveness of one round of [[MDA]] with [[FDC]] vs [[albendazole]] against [[Strongyloides stercolaris]] by serology
|
|
- Primary goal: Safety (incidence of SAEs)
|
|
- Secondary goals:
|
|
- Effectiveness at 21 days and 1 year
|
|
- Genomic resistance
|
|
- Sample size:
|
|
- Nuestros objetivos:
|
|
- Overall goal: Support the achievement of the [[WHO]] 2030 NTD Roadmap for [[STH]] and beyond
|
|
- Project purpose: Advance and accelerate an innovative pharmacological tool to support the elimination goals against [[STH]] species, especially those poorly responsive to current treatment regimens |